Valuation: IXICO plc

Market Cap 18.53M 24.66M 21.64M 20.15M 34.74M 2.36B 35.34M 239M 93.57M 1.17B 92.57M 90.57M 4.04B P/E 2026 *
-6.07x
P/E 2027 * -6.54x
Enterprise Value 8.33M 11.09M 9.73M 9.06M 15.62M 1.06B 15.89M 107M 42.08M 525M 41.62M 40.73M 1.81B EV / Sales 2026 *
1.04x
EV / Sales 2027 * 1.38x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 24.66M
+0.14%-0.67%-0.88%+11.02% 47.74B
-2.40%-0.38%+390.04%+610.19% 39.98B
+0.71%+2.64%+11.06%+45.29% 36.23B
+13.61%+19.43%+21.76%+6.47% 35.59B
-0.73%+2.78%+4.65%+41.16% 27.91B
-1.93%-2.81% - - 16.71B
-0.76%+9.63%+28.66%+128.75% 16.45B
+2.39%-1.64%+4.74%+9.95% 13.21B
+7.48%+8.85%-4.38%-28.07% 12.93B
Average -3.47%+2.78%+56.96%+103.09% 27.42B
Weighted average by Cap. +2.01%+2.95%+75.35%+129.67%

Financials

2026 *2027 *
Net sales 8M 10.64M 9.34M 8.7M 15M 1.02B 15.25M 103M 40.39M 504M 39.96M 39.09M 1.74B 9M 11.97M 10.51M 9.79M 16.87M 1.14B 17.16M 116M 45.44M 567M 44.95M 43.98M 1.96B
Net income -2.14M -2.85M -2.5M -2.33M -4.02M -272M -4.09M -27.64M -10.82M -135M -10.7M -10.47M -467M -2.8M -3.73M -3.27M -3.05M -5.25M -356M -5.34M -36.13M -14.14M -177M -13.99M -13.69M -610M
Net Debt -10.2M -13.57M -11.91M -11.09M -19.12M -1.3B -19.45M -132M -51.5M -643M -50.94M -49.84M -2.22B -6.1M -8.12M -7.12M -6.63M -11.43M -775M -11.63M -78.68M -30.8M -385M -30.47M -29.81M -1.33B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0850GBP
Average target price
0.2600GBP
Spread / Average Target
+205.88%

Annual profits - Rate of surprise